Merck’s Investigational 9-valent HPV Vaccine, V503, Prevented 97 Percent of Cervical, Vaginal and Vulvar Pre-cancers Caused by Five Additional HPV Types, in Phase III Study
Dateline City:
WHITEHOUSE STATION, N.J.
Immunogenicity non-inferior to GARDASIL® for original four HPV types
Merck expects to file Biologics License Application with U.S. FDA in 2013
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
announced today that in the pivotal Phase III efficacy study, its
investigational 9-valent HPV vaccine (V503) prevented approximately 97
percent of cervical, vaginal and vulvar pre-cancers caused by HPV types
31, 33, 45, 52, and 58.
Language:
English
Contact:
Media:Pamela Eisele, 908-423-5042orImraan Munshi, 215-652-0059orInvestor:Carol Ferguson, 908-423-4465orJustin Holko, 908-423-5088
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more
Source: Merck.com - Research and Development News - Category: Pharmaceuticals Tags: Research and Development News Corporate News Latest News Source Type: news
More News: Cancer | Cancer & Oncology | Cancer Vaccines | Cervical Cancer | Merck | Pharmaceuticals | Study | Vaccines